Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-β-induced phosphorylation of ERK
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Adult cardiac valve endothelial cells (VEC) undergo endothelial to mesenchymal transformation (EndMT) in response to transforming growth factor-β (TGFβ). EndMT has been proposed as a mechanism to replenish interstitial cells that reside within the leaflets and further, as an adaptive response that increases the size of mitral valve leaflets after myocardial infarction. To better understand valvular EndMT, we investigated TGFβ-induced signaling in mitral VEC, and carotid artery endothelial cells (CAEC) as a control. Expression of EndMT target genes α-smooth muscle actin (α-SMA), Snai1, Slug, and MMP-2 were used to monitor EndMT. We show that TGFβ-induced EndMT increases phosphorylation of ERK (p-ERK), and this is blocked by Losartan, an FDA-approved antagonist of the angiotensin II type 1 receptor (AT1), that is known to indirectly inhibit phosphorylation of ERK (p-ERK). Blocking TGF-β-induced p-ERK directly with the MEK1/2 inhibitor RDEA119 was sufficient to prevent EndMT. In mitral VECs, TGFβ had only modest effects on phosphorylation of the canonical TGF-β signaling mediator mothers against decapentaplegic homolog 3 (SMAD3). These results indicate a predominance of the non-canonical p-ERK pathway in TGFβ-mediated EndMT in mitral VECs. AT1 and angiotensin II type 2 (AT2) were detected in mitral VEC, and high concentrations of angiotensin II (AngII) stimulated EndMT, which was blocked by Losartan. The ability of Losartan or MEK1/2 inhibitors to block EndMT suggests these drugs may be useful in manipulating EndMT to prevent excessive growth and fibrosis that occurs in the leaflets after myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Development of heart valves requires Gata4 expression in endothelial-derived cells
Rivera-Feliciano, J., Lee, K.-H., Kong, S. W., Rajagopal, S., Ma, Q., Springer, Z., Izumo, S., Tabin, C. J., & Pu, W. T. (2006) · Development · doi:10.1242/dev.02519 · Cited by 190 · cited 1×
“In 2006, phosphorylation of ERK was shown to be required for EndMT in the atrioventricular cushions of developing murine embryos [19].”
BackgroundNfatc1 Coordinates Valve Endocardial Cell Lineage Development Required for Heart Valve Formation
Wu, B., Wang, Y., Lui, W., Langworthy, M., Tompkins, K. L., Hatzopoulos, A. K., Baldwin, H. S., & Zhou, B. (2011) · Circulation Research · doi:10.1161/circresaha.111.245035 · Cited by 182 · cited 1×
“NFATc1 is a transcription factor expressed in the endocardial cushions that has been shown to mark endothelial cells that do not undergo EndMT and instead proliferate [16,17]; this indicates that NFATc1 is inversely correlated with EndMT.”
Background
Cited by
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
TGF-β Signaling in Control of Cardiovascular Function
Goumans, M.-J., & ten Dijke, P. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022210 · Cited by 360
Getting to the Heart of the Matter: New Insights Into Cardiac Fibrosis
Leask, A. (2015) · Circulation Research · doi:10.1161/circresaha.116.305381 · Cited by 340
Cho, J. G., Lee, A., Chang, W., Lee, M.-S., & Kim, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00294 · Cited by 284
“Similarly, losartan and irbesartan, two angiotensin II-receptor type 1 blockers, ameliorate cardiac fibrosis by inhibiting EndMT (61, 102).”
BackgroundEndothelial-Mesenchymal Transition in Cardiovascular Disease
Alvandi, Z., & Bischoff, J. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.313788 · Cited by 218
Self-citationMechanobiology of myofibroblast adhesion in fibrotic cardiac disease
Schroer, A. K., & Merryman, W. D. (2015) · Journal of Cell Science · doi:10.1242/jcs.162891 · Cited by 127
“These cells lose their endothelial adhesions, including vascular-endothelial (VE)cadherin, and express migratory, mysenchymal cell markers, including N-cadherin, matrix metalloproteinase 2 (MMP2) and α-SMA (Wylie-Sears et al., 2014).”
Background
Metadata
- Authors
- Wylie-Sears, J., Levine, R. A., & Bischoff, J.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 446
- Issue
- 4
- Pages
- 870-875
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2091780020
- Cited by
- 102
- References
- 3
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.